This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT502 administered subcutaneously to participants with Rheumatoid Arthritis (RA). The study will have 2 parts: Part A is a single ascending dose finding (SAD) and Part B is dose escalation by fractionated dosing.
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Incidence of Adverse Events
Timeframe: From Baseline Up to 12 weeks
Incidence of Cytokine-release Syndrome (CRS)
Timeframe: From Baseline Up to 12 Weeks
Changes in Pulse Rate from Baseline
Timeframe: From Baseline Up to 12 Weeks
Changes in Respiratory Rate from Baseline
Timeframe: From Baseline to 12 Weeks
Changes in Blood Pressure from Baseline
Timeframe: Baseline to 12 Weeks
Changes in Temperature from Baseline
Timeframe: Baseline to 12 Weeks
Changes in Hematology Clinical Laboratory Results from Baseline
Timeframe: From Baseline Up to 12 Weeks
Changes in Chemistry Clinical Laboratory Results from Baseline
Timeframe: From Baseline Up to 12 Weeks
Changes in Urinalysis Clinical Laboratory Results from Baseline
Timeframe: Baseline Up to 12 Weeks
Changes in Coagulation Clinical Laboratory Results from Baseline
Timeframe: From Baseline Up to 12 Weeks
ECG
Timeframe: From Baseline to 12 Weeks